Champions Oncology announced on April 28, 2025, that it has been granted a license to use radioactive materials in preclinical studies. This regulatory approval significantly expands the organization's capabilities in oncology research.
The license allows Champions Oncology to conduct in-house work utilizing a variety of clinically relevant radionuclides. This capability is crucial for the development and assessment of targeted radiotherapeutics.
This development positions Champions Oncology to offer comprehensive services in a rapidly growing and specialized area of cancer treatment. The ability to perform these studies in-house enhances its service portfolio and competitive advantage in translational oncology research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.